凝血酶抑制剂比伐卢定的临床应用

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (3): 339-343.

凝血酶抑制剂比伐卢定的临床应用

何燕¹, 王良友²

¹苏州大学医学部放射医学与防护学院,苏州 215123,江苏
²苏州中科天马肽工程中心有限公司,苏州 215101,江苏

收稿日期:2012-06-16 修回日期:2012-11-30 出版日期:2013-03-26 发布日期:2013-04-02
通讯作者: 王良友,男,通信作者,技术总监/副研究员,研究方向:多肽药物的合成与修饰。E-mail: liangywang@gmail.com
作者简介:何燕,女,本科在读。E-mail: justmine6@126.com
基金资助:
江苏省“大学生实践创新训练计划”项目(5731504610)

Inhibitor of thrombin, bivalirudin

HE Yan¹, WANG Liang-you²

¹Institute of Radiological Medicine and Protection, Suzhow University,Suzhou 215123,Jiangsu,China
²Peptide Engineering Center of Suzhou Zhongke Tianma Co. Ltd,Suzhou 215101,Jiangsu,China

Received:2012-06-16 Revised:2012-11-30 Online:2013-03-26 Published:2013-04-02

摘要/Abstract

摘要： 比伐卢定是2000年被FDA批准上市的抗凝血药物,它通过直接抑制凝血酶发挥抗凝作用,已被批准应用于PCI/PTCA、HIT/HITTS、ACS 等领域。现有研究表明比伐卢定在临床抗凝治疗中有较好的安全性,可以用于常规治疗方案(肝素与糖蛋白IIb/IIIa抑制剂)的替代治疗,而且可以降低出血风险和死亡率。本文主要介绍凝血酶直接抑制剂比伐卢定的药理作用及临床研究,总结分析其安全性及经济效益,并且结合国内临床应用情况,分析其在国内的临床运用前景。

关键词: 比伐卢定, 凝血酶抑制剂, 临床研究, 经济效益

Abstract: Bivalirudin was approved by US Food and Drug Administration as a new direct inhibitor of thrombin in 2000, the drug was currently approved the application to PCI / PTCA, HIT / HITTS, ACS etc. Existing research shows bivalirudin have a better security and can be used for the classic treatment regimens ( heparin and glycoprotein IIb/IIIa inhibitors ) alternative treatment, Moreover, it can reduce the risk of bleeding and mortality. This paper analysis the mechanism of action, pharmacokinetics, pharmacodynamics, clinical application, safety and cost-effectiveness of bivalirudin. But it limited in application in the domestic market, thus strengthening the clinical trails research is promising.

Key words: Bivalirudin, Direct inhibitor of thrombin, Clinical trail, Cost-Effectiveness

中图分类号:

何燕, 王良友. 凝血酶抑制剂比伐卢定的临床应用[J]. 中国临床药理学与治疗学, 2013, 18(3): 339-343.

HE Yan, WANG Liang-you. Inhibitor of thrombin, bivalirudin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 339-343.

参考文献

[1] Reed MD, Bell D. Clinical pharmacology of bivalirudin[J]. Pharmacotherapy,2002,22(2):105-111.
[2] Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors[J]. J Invasive Cardiol,2000,12:27-32.
[3] Centurion OA.Bivalirudin in contemporary percutaneous coronary intervention for non-st-segment elevation acute coronary syndromes: what is the current role of platelet glycoprotein iib/iiia receptor inhibitor agents[J] ? Crit Pathw Cardiol, 2011,10(2):87-92.
[4] Sciulli TM, Mauro VF .Pharmacology and clinical use of bivalirudin[J]. Ann Pharmacother,2002, 36(6):1028-1041.
[5] Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention[J]. Am J Health Syst Pharm, 2003,60(18): 1841-1849.
[6] Robson R, White H, Aylward P, et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender[J]. Clin Pharmacol Ther,2002,71(6):433-439.
[7] Timothy D.Bivalirudin: a direct thrombin inhibitor[J]. Clin Ther, 2002,24(1): 38-58.
[8] Rassen JA, Mittleman MA, Glynn RJ,et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention[J].Eur Heart J,2010,31(5):561-572.
[9] Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes[J]. N Engl J Med,2006,355(21):2203-2216.
[10] Bittl JA, Strony J, Brinker JA,et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators[J]. N Engl J Med,1995,333(12):764-769.
[11] Yavin YY,Wolozinsky M,Cohen AT,et al. New antithrombotics in the prevention of thromboembolic disease[J]. Eur J Intern Med,2005,16(4): 257-266.
[12] Lincoff AM, Bittl JA, Kleiman NS,et al. The REPLACE-1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade free[J]. J Am Coll Cardiol,2002,39(s1):16-17.
[13] Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial[J]. JAMA,2003,289(7):853-863.
[14] Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction.[J] , N Engl J Med, 2008,358(21): 2218-2230.
[15] Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial[J].Lancet, 2009,374(9696): 1149-1159.
[16] 权菊香,王燕龙.直接凝血酶抑制剂比伐卢定的研究现状[J].中国临床药理学杂志,2012,3(28):231-233.
[17] Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the choose-on trial[J]. Ann Thorac Surg,2007,83(2):572-577.
[18] Alan F, Peter J, Neil G. et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery[J]. Ann Thorac Surg,2004, 77 (3): 925-931.
[19] Koster A, Spiess B, Jurmann M, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the “evolution off” trial[J]. Anesth Analg,2006, 103(3):540-544.
[20] 杨士伟,周玉杰.2011年美国不稳定型心绞痛和非ST段抬高心肌梗死治疗指南-解读与实践[J].中国医学前沿杂志,2011,5(3):100-105.
[21] Dyke CM, Koster A, Veale JJ, et al. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.Cornelius[J]. Ann Thorac Surg,2005,80(1):299-303.
[22] Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention[J]. Pharmacotherapy,2002,22(6 Pt 2):97-104.
[23] Zhang D, Wang Z, Zhao X, et al. Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects[J]. Biol Pharm Bull,2011,34(12):1841-1848.
[24] 柴栋,王睿,白楠,等.注射用比伐卢定在中国健康受试者的耐受性研究[J].中国药物应用与监测,2011,3(8):136-138 .
[25] 向定成.国产比伐卢定用于冠状动脉介入治疗术中抗凝的疗效和安全性评价[J].中国循环杂志,2011,5(26):331-334.
[26] Amin AP, Marso SP, Rao SV, et al.Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding[J]. Circ Cardiovasc Qual Outcomes,2010,3(4):358-365.
[27] Pinto DS, Ogbonnaya A, Sherman SA, et al. Bivalirudin therapy is associated with improved clinical and economic outcomes in st-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database[J]. Circ Cardiovasc Qual Outcomes,2012,5(1):52-61.
[28] Kessler DP, Kroch E, Hlatky MA,et al. The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction[J]. Am Heart J,2011,162(3):494-500.
[29] 王良友,潘和平,柳川,等.人甲状旁腺素(1-34)的合成与聚乙二醇化修饰[J].中国生化药物杂志,2005,2(26):76-79,89.